Fig. 7: Pharmacokinetics (PK) and biocompatibility of C-Mn3O4 NPs.
From: Redox nanomedicine ameliorates chronic kidney disease (CKD) by mitochondrial reconditioning in mice
a Plasma concentration-time profile following intraperitoneal administration of C-Mn3O4 NPs as measured using inductively coupled plasma-atomic emission spectroscopy (ICP-AES). Inset shows the PK parameters calculated using a non-compartmental approach. The dotted line is a guide to the eye. b Time-dependent accumulation and elimination of C-Mn3O4 NPs in the kidney. Data were normalized to wet kidney weight. c Micrographs of hematoxylin and eosin-stained sections of different organs after 1 month of treatment with the therapeutic dose (0.25 mg kg−1 body weight, i.p.) of C-Mn3O4 NPs. Both control and treated animals maintained normal tissue architecture. Scale bars: liver-100 µm, brain-50 µm, ovary-20 µm, pancreas-50 µm, spleen-100 µm, testes-100 µm. Data were expressed as Mean ± SD. Individual data points are represented as white circles (N = 5).
